Baird R W Upgrades Alumis (NASDAQ:ALMS) to “Strong-Buy”

Alumis (NASDAQ:ALMS) was upgraded by investment analysts at Baird R W to a “strong-buy” rating in a note issued to investors on Thursday, Zacks.com reports.

ALMS has been the subject of several other research reports. Leerink Partners started coverage on Alumis in a report on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price objective for the company. Leerink Partnrs upgraded Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Morgan Stanley started coverage on Alumis in a report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price target for the company. Robert W. Baird started coverage on Alumis in a report on Thursday. They set an “outperform” rating and a $25.00 price target for the company. Finally, HC Wainwright started coverage on Alumis in a report on Thursday, October 17th. They set a “buy” rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Alumis currently has a consensus rating of “Buy” and a consensus price target of $27.50.

Alumis Stock Down 0.1 %

NASDAQ ALMS opened at $11.31 on Thursday. Alumis has a 52 week low of $9.54 and a 52 week high of $13.53. The firm’s 50 day moving average price is $11.48.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, equities analysts anticipate that Alumis will post -8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Maven Securities LTD bought a new position in Alumis in the 2nd quarter valued at $332,000. Millennium Management LLC bought a new position in Alumis in the 2nd quarter valued at $3,376,000. Towerview LLC bought a new position in Alumis in the 2nd quarter valued at $4,123,000. Ally Bridge Group NY LLC bought a new position in Alumis in the 2nd quarter valued at $8,229,000. Finally, Yu Fan bought a new position in Alumis in the 2nd quarter valued at $10,502,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.